Positron Announces Sales of Tech-Assist(TM) Units to Top Medical Institutions

Positron Corporation (OTCBB:POSC), a molecular imaging solutions company focused on Nuclear Cardiology, announces sales of the Tech-Assist(TM) to a number of top institutes in the United States. Positron provides a cost effective, radiation shielding device with the Tech-Assist(TM). The Tech-Assist(TM) is a portable dose administration system utilized during Fluorodeoxyglucose F-18 (FDG) injections for Positron Emission Tomography (PET) studies.

The Tech-Assist(TM) provides enhanced tungsten shielding, increased distance and reduction of time spent in proximity to the radioactive source during transport and the injection process. "The Tech-Assist(TM) is the most efficient product in its class for effectively reducing radiation. Positron has had a tremendous acceptance from its oncology based users and expects significant growth as F-18 cardiac agents become available," states John A. Zehner, COO of Positron.

Since its release earlier this year, the Tech-Assist(TM) has been met with wide acclaim within the Nuclear Medicine industry. One of the luminary institutions where the Tech-Assist(TM) is being utilized is Mount Sinai School of Medicine. "The Tech-Assist(TM) is the easiest, most versatile injector made for administering FDG, it has reduced our occupational exposure levels by over 50%," states Ash Rafique, Mount Sinai Medical Center, NY Nuclear Medicine/PET-CT Supervisor CNMT, B.S.

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

SOURCE: Positron Corporation

Positron Corporation 
John Zehner R.Ph., (317)576-0183

Related terms: community, connecticut, medical, medicine, new york, nuclear, products, sales